Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy

被引：0
|
作者：
Mohyuddin, Ghulam Rehman [1 ]
Chakraborty, Rajshekhar [2 ]
Calip, Gregory S. [3 ]
Ascha, Mustafa S. [3 ]
Wang, Xiaoliang [3 ]
Rubinstein, Samuel M. [4 ]
Tuchman, Sascha [4 ]
Costa, Luciano [5 ]
Haaland, Benjamin [6 ]
Giri, Smith [5 ]
Mian, Hira [7 ]
Fonseca, Rafael [8 ]
Sborov, Douglas [1 ]
机构：
[1] Univ Utah, Huntsman Canc Inst, Div Hematol & Hematol Malignancies, Salt Lake City, UT 84112 USA
[2] Columbia Univ, Dept Hematol, New York, NY USA
[3] Flatiron Hlth, New York, NY USA
[4] Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, Dept Med, Div Hematol, Chapel Hill, NC USA
[5] Univ Alabama Birmingham, Div Hematol & Oncol, Birmingham, AL USA
[6] Univ Utah, Dept Populat Sci, Salt Lake City, UT USA
[7] McMaster Univ, Dept Oncol, Hamilton, ON, Canada
[8] Mayo Clin Arizona, Div Hematol & Oncol, Phoenix, AZ USA
来源：
BLOOD CANCER JOURNAL | 2022年 / 12卷 / 12期
关键词：
D O I：
10.1038/s41408-022-00769-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Efficacy and Safety of Anti-CD38 Monoclonal Antibodies in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Randomized Clinical Trials
    de Moraes, Francisco Cezar Aquino
    Sano, Vitor Kendi Tsuchiya
    Lobo, Artur de Oliveira Macena
    Kelly, Francinny Alves
    Morbach, Victoria
    Pasqualotto, Eric
    Burbano, Rommel Mario Rodriguez
    JOURNAL OF PERSONALIZED MEDICINE, 2024, 14 (04):
  • [22] Analyzing Risk of Infection with Anti-CD38 Monoclonal Antibody Therapy for Patients with Multiple Myeloma
    Hong, Augustine
    Eduafo, Augusta
    Schmikla, Hannah
    Brown, George
    Ravi, Gayathri
    de Lima, Marcos
    Malek, Ehsan
    BLOOD, 2020, 136
  • [23] Venetoclax-dexamethasone combination: the solution for relapsed/refractory myeloma with translocation 11;14?
    Helene, Gardeney
    Xavier, Leleu
    Cecile, Gruchet
    HEMATOLOGIE, 2021, 27 (03): : 108 - 109
  • [24] Anti-CD38 Therapy with Daratumumab for Relapsed/Refractory CD20-Negative Diffuse Large B-Cell Lymphoma
    Vockova, P.
    Svaton, M.
    Karolova, J.
    Pokorna, E.
    Vokurka, M.
    Klener, P.
    FOLIA BIOLOGICA, 2020, 66 (01) : 17 - 23
  • [25] A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma
    Mikhael, Joseph
    Richter, Joshua
    Vij, Ravi
    Cole, Craig
    Zonder, Jeffrey
    Kaufman, Jonathan L.
    Bensinger, William
    Dimopoulos, Meletios
    Lendvai, Nikoletta
    Hari, Parameswaran
    Ocio, Enrique M.
    Gasparetto, Cristina
    Kumar, Shaji
    Oprea, Corina
    Chiron, Marielle
    Brillac, Claire
    Charpentier, Eric
    San-Miguel, Jesus
    Martin, Thomas
    LEUKEMIA, 2020, 34 (12) : 3298 - 3309
  • [26] A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma
    Joseph Mikhael
    Joshua Richter
    Ravi Vij
    Craig Cole
    Jeffrey Zonder
    Jonathan L. Kaufman
    William Bensinger
    Meletios Dimopoulos
    Nikoletta Lendvai
    Parameswaran Hari
    Enrique M. Ocio
    Cristina Gasparetto
    Shaji Kumar
    Corina Oprea
    Marielle Chiron
    Claire Brillac
    Eric Charpentier
    Jesús San-Miguel
    Thomas Martin
    Leukemia, 2020, 34 : 3298 - 3309
  • [27] IMiD Retreatment in Patients Refractory to Both an IMiD and an Anti-CD38 Antibody Induces Significant Response Rates Post Anti-CD38 Exposure
    Gavriatopoulou, Maria
    Ntanasis-Stathopoulos, Ioannis
    Malandrakis, Panagiotis
    Fotiou, Despina
    Migkou, Magdalini
    Kanellias, Nikolaos
    Eleutherakis-Papaiakovou, Evangelos
    Dialoupi, Ioanna
    Theodorakakou, Foteini
    Roussou, Maria
    Terpos, Evangelos
    Kastritis, Efstathios
    Dimopoulos, Meletios A.
    BLOOD, 2020, 136
  • [28] A CD38/CD3xCD28 trispecific T-cell engager as a potentially active agent in multiple myeloma patients relapsed and/or refractory to anti-CD38 monoclonal antibodies
    Zabaleta, Aintzane
    Blanco, Laura
    Kim, Peter S.
    Bisht, Kamlesh
    Wang, Hongfang
    Van de Velde, Helgi
    Lasa, Marta
    Tamariz-Amador, Luis-Esteban
    Rodriguez-Otero, Paula
    San-Miguel, Jesus
    Paiva, Bruno
    Martin-Sanchez, Esperanza
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (06) : 2262 - 2267
  • [29] Myeloma Patients Receiving Daratumumab (Anti-CD38) Can Appear to Have an Antibody with Lutheran-related Specificity
    Aye, T.
    Arndt, P. A.
    Leger, R. M.
    Do, J.
    Rodberg, K.
    Aldridge, L.
    Wang, S.
    TRANSFUSION, 2015, 55 : 28A - 28A
  • [30] Excellent response to anti-CD38 therapy with daratumumab in a patient with severe refractory CANOMAD
    Pascual-Goni, Elba
    Collet, Roger
    Tejada-Illa, Clara
    Martin-Aguilar, Lorena
    Caballero-Avila, Marta
    Lleixa, Cinta
    Novelli, Silvana
    Lopez-Pardo, Jordi
    Sanfeliu, Albert Esquirol
    Mariscal, Anais
    Gargallo, Yolanda Alvaro
    Martinez-Hernandez, Eugenia
    Cocho, Dolores
    Querol, Luis
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2024, 95 (07): : 609 - 611
12345